SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-23-000590
Filing Date
2023-05-16
Accepted
2023-05-16 16:28:45
Documents
2
Group Members
ORBIMED CAPITAL GP VII LLCORBIMED CAPITAL LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 ss2080993_sc13da.htm SC 13D/A 108215
2 JOINT FILING AGREEMENT ss2080993_ex9901.htm EX-99.1 5950
  Complete submission text file 0000947871-23-000590.txt   115728
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Subject) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91552 | Film No.: 23927953
SIC: 2836 Biological Products, (No Diagnostic Substances)